Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)
- First Posted Date
- 2017-06-06
- Last Posted Date
- 2022-02-16
- Target Recruit Count
- 85
- Registration Number
- NCT03177239
- Locations
- 🇦🇺
Campbelltown Hospital, Campbelltown, New South Wales, Australia
🇦🇺Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺Northern Cancer Institute, Frenchs Forest, New South Wales, Australia
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT03172624
- Locations
- 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
- Conditions
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 15
- Registration Number
- NCT03168464
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
- Conditions
- Interventions
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT03166397
- Locations
- 🇮🇱
Sheba Medical Center, Ramat Gan, Israel
Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 72
- Registration Number
- NCT03161756
- Locations
- 🇦🇺
Royal Hobart Hospital, Hobart, Tasmania, Australia
🇦🇺Box Hill Hospital, Box Hill, Victoria, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Takara Bio Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT03153085
- Locations
- 🇯🇵
Clinical Site, Ōsaka, Japan
Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
- Conditions
- Interventions
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2018-06-18
- Lead Sponsor
- Medical University of South Carolina
- Registration Number
- NCT03149159
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Sarcoma Oncology Research Center, LLC
- Target Recruit Count
- 45
- Registration Number
- NCT03138161
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
- Conditions
- Interventions
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1641
- Registration Number
- NCT03138512
- Locations
- 🇺🇸
Local Institution - 0019, Birmingham, Alabama, United States
🇺🇸Local Institution - 0056, Springdale, Arkansas, United States
🇺🇸Local Institution - 0186, Los Angeles, California, United States
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
- Conditions
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT03126331
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.